Encodia, a San Diego, CA-based biotech company developing next-generation solutions for proteomics research, closed a $75m Series C financing.
The round was led by Northpond Ventures and Deerfield Management, joined by GV, Alexandria Venture Investments, and existing investors ARCH Venture Partners, Biomatics Capital, Decheng Capital, Tao Capital Partners, and Nan Fung Life Sciences. In conjunction with the funding, Sharon Kedar of Northpond and Dr. Andrew ElBardissi of Deerfield Management are joining Encodia’s Board of Directors.
The company intends to use the funds to accelerate productization of its patented ProteoCode™ platform for broad use in life science research and subsequent clinical applications.
Founded by Drs. Mark Chee (President), Kevin Gunderson (CTO), and Michael Weiner (Board member), a team with experience inventing, developing, and commercializing transformative platform technologies and assays, Encodia is a biotechnology company bringing sequencing to proteomics. The company’s patented ProteoCode technology enables highly scalable protein analysis via an accessible and easy-to-use benchtop instrument. Tools employing its ProteoCode technology will drive new biological understanding with impact in data-driven drug discovery and development, new high-complexity diagnostics, and beyond.